Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use

Summary

This Phase 1 clinical trial will evaluate MIV-150, a third generation non-nucleoside reverse transcriptase inhibitor, co-formulated with a potentially potent agent, zinc acetate for the prevention of HIV infection in women. This is the first in-human of PC-1005 (MIV-150/zinc acetate in a carrageenan gel), the first study in which females will be exposed to MIV-150, the first time MIV-150 will be administered topically, and the first time MIV-150 will be administered intravaginally.

Timeline

Start

2014-05

Primary completion

2015-04

Completion

2015-06

Drugs

Indications